Galantamine Hydrobromide is a rapidly and completely absorbed drug but plasma level achieved is highly variable after oral administration. Besides it also has relatively short elimination half-life is 7 to 8 hours. A drug with a short half-life requires frequent dosing and this makes Galantamine Hydrobromide an ideal candidate for a sustainedrelease formulation. Hydrophilic and swallable polymer matrix systems are widely used in sustained-release delivery because of their flexibility to obtain a desirable drug release profile. Cost effectiveness and broad regulatory acceptance. To provide a bi-layer sustained-release composition which releases Galantamine Hydrobromide from both immediate and sustained release layer, over a time period of at least about 24 hours. To develop a bi-layer dosage form that immediate release layer contain the loading dose and sustained release layer contain the maintenance dose of drug.
